The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Alpha-synuclein Pathology, 2014Contrasting Pathological Versus Normal Alpha-synuclein Assemblies
Study Rationale:
Parkinson’s disease (PD) is characterized by Lewy bodies composed of the protein alpha-synuclein in dopamine-producing nerve cells. The protein aggregates are also... -
Research Grant, 2015VPAC2 Agonists Neuroprotective and Anti-inflammatory Effects in Parkinson's Disease
Study Rationale:
The adaptive and innate immune responses play intricate roles in modulating neuroinflammation and may be harnessed for neuroprotection from Parkinson’s disease. We... -
Alpha-synuclein Pathology, 2014Characterization and Validation of Disease-specific Alpha-synuclein Species
Study Rationale
Alpha-synuclein aggregates called Lewy bodies are the hallmark of Parkinson’s disease (PD). Methods to measure alpha-synuclein in cerebrospinal fluid do exist today. However, these... -
Alpha-synuclein Pathology, 2014Characterization and Validation of Disease-specific Alpha-synuclein Species in Cerebrospinal Fluid
Study Rationale:
The protein alpha-synuclein plays a major role in Parkinson’s disease (PD). Quantification of alpha-synuclein in biological fluids (e.g., cerebrospinal fluid) could... -
Access to Data and Biospecimens, 2014Purine Biomarkers of LRRK2 PD
Objective/Rationale:
Oxidative damage to brain cells — akin to rust on car parts — can build up in Parkinson’s disease (PD) and leads to break down of brain functions. Urate is a natural... -
Access to Data and Biospecimens, 2014LRRK2 in Urine as a Biomarker for PD
Objective/Rationale:
A mutation in the LRRK2 gene is the most common known genetic cause of Parkinson’s disease (PD). Not everyone who has the LRRK2 mutation will develop PD, but there are...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.